
Emily Jarvie
Financial Journalist at Proactive Investors
Financial journalist @proactive_ca @proactive_NA 💸
Articles
-
Oct 3, 2023 |
proactiveinvestors.com | Andrew Kessel |Emily Jarvie
About Andrew Kessel Andrew is a financial journalist with experience covering public companies in a wide breadth of industries, including tech, medicine, cryptocurrency, mining and retail. In addition to Proactive, he has been published in a Financial Times-owned newsletter covering broker-dealer firms and in the Columbia Misourian newspaper as the lead reporter focused on higher education. He got his start with an internship at Rolling Stone magazine.
-
Sep 12, 2023 |
proactiveinvestors.com | Andrew Kessel |Emily Jarvie
About Andrew Kessel Andrew is a financial journalist with experience covering public companies in a wide breadth of industries, including tech, medicine, cryptocurrency, mining and retail. In addition to Proactive, he has been published in a Financial Times-owned newsletter covering broker-dealer firms and in the Columbia Misourian newspaper as the lead reporter focused on higher education. He got his start with an internship at Rolling Stone magazine.
-
Sep 12, 2023 |
proactiveinvestors.com | Andrew Kessel |Emily Jarvie
About Andrew Kessel Andrew is a financial journalist with experience covering public companies in a wide breadth of industries, including tech, medicine, cryptocurrency, mining and retail. In addition to Proactive, he has been published in a Financial Times-owned newsletter covering broker-dealer firms and in the Columbia Misourian newspaper as the lead reporter focused on higher education. He got his start with an internship at Rolling Stone magazine.
-
Sep 11, 2023 |
proactiveinvestors.com | Emily Jarvie
BioVie Inc (NASDAQ:BIVI) has unveiled early data from the Phase 3 study of its investigational drug NE3107 in patients with mild to moderate Alzheimer’s Disease, highlighting the preliminary baseline metabolic and inflammation characteristics of the study population. The update sent its shares higher, up 14% at US$3.92 late morning on Monday.
-
Aug 27, 2023 |
proactiveinvestors.com | Stephen Gunnion |Emily Jarvie
US stocks were higher in noon trading as investors brace for key inflation and employment data to be released later this week. At midday, the Dow rose 183 points to 34,530 while the S&P 500 added 15 points at 4,421 and the tech-heavy Nasdaq gained 50 points to 13,641. “Today is much more of a cyclical lift versus tech, and I think that’s just from stronger-than-expected growth outside of the US,” Certuity co-chief investment officer Dylan Kremer said.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 1K
- Tweets
- 2K
- DMs Open
- Yes

$IMUX Biotechs challenge big pharma with new oral weight loss therapies https://t.co/TLGZ7zM3lP @ImmunicInc #IMUX

Could the Super Bowl decide the stock market’s next move? History says maybe https://t.co/bHNydSRVUq

RT @ErasTourResell: SURPRISE!!!! We are doing a giveaway for a pair of tickets for the show in Toronto TOMORROW 11/22! Like, Repost, & a fr…